anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Metabolic flexibility is the ability to match biofuel availability to utilization and is inversely associated with increased metabolic burden among liver transplant (LT) recipients. The present study evaluated the impact of metabolic flexibility on weight gain following LT. LT recipients were enrolled prospectively (n = 47) and followed for 6 months. Metabolic flexibility was measured using whole-room calorimetry and is expressed as a respiratory quotient (RQ). Peak RQ represents maximal carbohydrate metabolism and occurs in the post-prandial state, while trough RQ represents maximal fatty acid metabolism occurring in the fasted state. The clinical, metabolic, and laboratory characteristics of the study cohort of lost weight (n = 14) and gained weight (n = 33) were similar at baseline. Patients who lost weight were more likely to reach maximal RQ (maximal carbohydrate oxidation) early and rapidly transitioned to trough RQ (maximal fatty acid oxidation). In contrast, patients who gained weight had delayed time to peak RQ and trough RQ. In multivariate modeling, time to peak RQ (β-coefficient 0.509, p = 0.01), time from peak RQ to trough RQ (β-coefficient 0.634, p = 0.006), and interaction between time to peak RQ to trough RQ and fasting RQ (β-coefficient 0.447, p = 0.02) directly correlated with the severity of weight gain. No statistically significant relationship between peak RQ, trough RQ, and weight change was demonstrated. Inefficient transition between biofuels (carbohydrates and fatty acids) is associated with weight gain in LT recipients that is independent of clinical metabolic risk. These data offer novel insight into the physiology of obesity after LT with the potential to develop new diagnostics and therapeutics.
The invention discloses ephedra, cassia twig, scorpion, centipede and woodlouse powders for treating lumbar intervertebral disc protrusion through a two-step method, and relates to traditional Chinese medicine powders for treating lumbar sprain and lumbar disc herniation. The ephedra, cassia twig, scorpion, centipede and woodlouse powders can treat lumbar sprain through the two-step method. In the first step, an ephedra and cassia twig juicing method is adopted to prompt a nucleus pulposus protrusion to retract so as to release the oppressed state of adjacent nerve roots and eliminate tissue edema around spinal cord and the spinal stenosis, so that pains of a patient that arrests sweating can be reduced immediately, and immediate effect can be achieved. In the second step, the scorpion, centipede and woodlouse powders are taken orally for one or two courses of treatment, each course of treatment contains ten days so as to restore broken fiber rings, and the disease can be healed thoroughly without recurrence. Ephedra and cassia twig are taken and ground to obtain fine powders that are 100 meshes (monopack), and scorpion, centipede and woodlouse are taken and ground to obtain fine powders that are 100 meshes (monopack). The ephedra and cassia twig powders are taken orally in the first day in the first course of treatment, and the patient covers a quilt for sweating. The scorpion, centipede and woodlouse powders are taken orally from the second day to the eleventh day, are taken two times a day in morning and evening respectively. After the first course of treatment, the patient suffered from the disease for a long time can take the powders for the second course of treatment, so as to achieve healing.
A method for generating a drug formulary or monograph including publicly available information and privately available information. A plurality of the generated monographs are stored and useful information is extracted from each of the monographs to improve patient healthcare outcomes. The extracted information provides an insight into the requested use or actual use by a patient or a medical facility of a prescription or non-prescription drug. For instance, the frequency of certain types of drug monographs could indicate a trend in the treatment of certain ailments and diseases. The drug formularies could indicate regions of the country where certain drugs are more often prescribed or requested. This indicator could be used by a drug manufacturer to increase production of a certain drug or increase the delivery to a certain region, or by a healthcare practitioner to determine which disease conditions or ailments occur more often and which require increased monitoring.
Placebo is contained within a single-use applicator. The placebo applicator consists of a plastic tube containing a sealed glass ampule and an applicator tip. One ampule contains 450μl of placebo solution with the same color and consistency as VP-102.
PURPOSE: A hydrogel mask pack and a manufacturing method thereof are provided to improve the transfer of active material to the skin. CONSTITUTION: A manufacturing method of a hydrogel mask pack is as follows. A mask pack(10) solution is applied to a film in which grooves and protrusions are formed. The film is cooled. A mask pack is separated from the film. An active material is added to the mask pack. The mask pack solution comprises carrageenan, locust gum, guar gum, and agar.
Extracellular vesicles (EVs) exert a significant influence not only on the pathogenesis of diseases but also on their therapeutic interventions, contingent upon the variances observed in their originating cells. Mitochondria can be transported between cells via EVs to promote pathological changes. In this study, we found that EVs derived from M1 macrophages (M1-EVs), which encapsulate inflammatory mitochondria, can penetrate pancreatic beta cells. Inflammatory mitochondria fuse with the mitochondria of pancreatic beta cells, resulting in lipid peroxidation and mitochondrial disruption. Furthermore, fragments of mitochondrial DNA (mtDNA) are released into the cytosol, activating the STING pathway and ultimately inducing apoptosis. The potential of adipose-derived stem cell (ADSC)-released EVs in suppressing M1 macrophage reactions shows promise. Subsequently, ADSC-EVs were utilized and modified with an F4/80 antibody to specifically target macrophages, aiming to treat ferroptosis of pancreatic beta cells in vivo. In summary, our data further demonstrate that EVs secreted from M1 phenotype macrophages play major roles in beta cell ferroptosis, and the modified ADSC-EVs exhibit considerable potential for development as a vehicle for targeted delivery to macrophages.
All consecutive patients who underwent robotic or laparoscopic right hemicolectomy with CME from July 2016 to July 2021 at three Chinese surgical departments (Department of General Surgery, Army Medical Center, Chongqing;Department of Colorectum, Chongqing University Three Gorges Hospital, Chongqing;Department of Colorectum, the 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Lanzhou) were included in the study. A retrospective review of multicenter institutional database was conducted. The Da Vinci Surgical System (Intuitive Surgical, Sunnyvale, CA, USA) has been employed since 2016 in three centers. From July 2016 to July 2021, an initial cohort of 412 consecutive patients underwent robotic or laparoscopic right hemicolectomy with CME in three departments. With 30 cases meeting the exclusion criteria, 382 cases, including 204 males and 178 females, were available for inclusion. Of these, 149 cases by robotic right hemicolectomy with CME were classified as the robotic group, while the other 233 cases by laparoscopic right hemicolectomy with CME as the laparoscopic group.
Bilateral shoulder AP standard plain x-ray in 0 and 90 degrees of arm abduction. Non-affected shoulder is used to be compared with the affected shoulder.
BACKGROUND: Physical activity and cardiorespiratory fitness are considered major markers of cardiovascular risk and core components of secondary prevention programs for cardiovascular diseases (CVD). The benefits of regular physical activity are well-recognized both for men and women and are inversely associated with mortality risk and the incidence of many chronic diseases. Despite the efforts of many health organizations to increase awareness of this evidence, physical inactivity and low cardiorespiratory fitness remain overlooked risk factors. Directly measured peak oxygen consumption (VO2peak) determined during maximal incremental cardiopulmonary exercise testing (CPX) is the gold standard objective measure of cardiorespiratory fitness. However, because of physical, financial, and time limitations, a direct determination is often not routinely assessed in clinical settings. Submaximal exercise testing can be a viable alternative to CPX. These tests are more practical for examining older adults or a large patient cohort. Also, they are helpful in defining functional limitations, setting up appropriate physical activity programs, and assessing the outcomes of pharmacological treatments.

RATIONALE AND OBJECTIVE OF THE STUDY: The benefits of regular physical activity are well-recognized both for men and women and are inversely associated with mortality risk and the incidence of many chronic diseases. The purpose of this observational registry is to evaluate the efficacy of an exercise-based secondary prevention program among male and female outpatients with stable cardiovascular disease.

DESCRIPTION OF THE FUNCTIONAL EVALUATION: During each session, information about weight, height, body mass index (BMI), blood pressure, cardiometabolic risk factors, and drug therapy in progress are registered. Physical activity habits are assessed using the Seven-Day Physical Activity Recall questionnaire. In addition, patients complete a sub-maximal test of 1km treadmill walking (1k-TWT), which is performed at a moderate intensity and adjusted according to the patient's perception of fatigue. Patients unable to complete the test at a walking speed ≥ 3.0 km/h can perform the test over 500m or 200m. Based on the results of the test, patients receive indications for the proper execution of a home training program, (i.e., at the same effort perceived in the test). The activity should be done at least 3-4 times per week, preferably every day, for at least 30-60 minutes. All patients are also encouraged to improve their daily habits by opting for a more active lifestyle at home and at work. Written informed consent is required from all participants at the time of enrollment.
The invention relates to an excipient used for medicinal preparation, concretely relates to a hollow capsule and its preparation method and application. The hollow capsule comprises, on a mass basis, 5-50% of inulin, 1-3% of a film forming agent, 2-5% of a plasticizer (ie, curing agent), 2-5% of a cross-linking agent (ie. coagulant), and the balance water. The capsule provided by the invention has the characteristics of good smooth shape, edibility, health care, and so on. The base material inulin itself is water-soluble meal fiber, which can provide certain nutrition to microbes in human guts, being stable in property and difficult to react with the medicine enclosed. The inulin hollow capsule is applicable for various populations, has good stability and is convenient for long time storage. Moreover, the process flow is simple, and the equipment can also be used for the production of gelatin capsule, saving production cost of the inulin capsule. And the indexes such as collapse time limit, and the breakage at different temperatures of the capsule are all meet the national standard of hollow capsules.
In a Phase 3 open-label randomized study conducted by the ECOG, 599 patients were randomized to either paclitaxel (T) 135 mg/m2 as a 24 hour infusion in combination with cisplatin (c) 75 mg/m2, paclitaxel (T) 250 mg/m2 as a 24 hour infusion in combination with cisplatin (c) 75 mg/m2 with G-CSF support, or cisplatin (c) 75 mg/m2 on day 1, followed by etoposide (VP) 100 mg/m2 on days 1, 2, and 3 (control).

Response rates, median time to progression, median survival, and 1 year survival rates are given in the following table. The reported p-values have not been adjusted for multiple comparisons. There were statistically significant differences favoring each of the paclitaxel plus cisplatin arms for response rate and time to tumor progression. There was no statistically significant difference in survival between either paclitaxel plus cisplatin arm and the cisplatin plus etoposide arm.

In the ECOG study, the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire had 7 subscales that measured subjective assessment of treatment. Of the 7, the Lung Cancer Specific Symptoms subscale favored the paclitaxel 135 mg/m2/24 hour plus cisplatin arm compared to the cisplatin/etoposide arm. For all other factors, there was no difference in the treatment groups.

The adverse event profile for patients who received paclitaxel in combination with cisplatin in this study was generally consistent with that seen for the pooled analysis of data from 812 patients treated with single-agent paclitaxel in 10 clinical studies. These adverse events and adverse events from the Phase 3 first-line NSCLC study are described in the ADVERSE REACTIONS section in tabular (TABLES 10 and 15) and narrative form.
Little is known of HPV vaccination (HPVV) recommendation practices among healthcare providers who treat the Arab American community. Evidence indicates that HPVV patient uptake is low in this population. A survey was administered to healthcare providers (N = 46, 63% response rate) who treated ≥ 5% Arab American patients aged 9-26 years in areas of New York City and New Jersey with large Arab American populations. They were asked about barriers to HPVV recommendation and uptake among their Arab American patients. Providers (Doctors of Medicine and Osteopathy, Nurse Practitioners, and Physician Assistants) mostly worked in pediatrics (41%), primary care/internal medicine (26%), obstetrics/gynecology (20%), and family medicine (15%). Most (91%) were confident in their ability to effectively counsel their patients on HPVV. The most frequent provider-reported barriers to administering the HPVV to Arab American patients were patient cultural/religious practices (reported by 67%) and patient and provider difficulties with insurance reimbursement (44%). Most providers (84%) agreed that organizations/programs to increase HPVV uptake among Arab American patients were needed. Providers felt that HPVV uptake could be increased with educational materials in the patients' native languages ("very useful," 81%) and provider cultural competency training ("very useful," 65%). In responses to open-ended questions, cultural and religious HPVV barriers were a salient topic, as were linguistic barriers and provider burdens related to HPVV costs and regulations. HPVV uptake could potentially be improved with Arabic language education materials, provider education that is culturally and linguistically tailored to the Arab American community, and policies to address HPVV financial and regulatory burdens.
Maintenance on a daily dose of oral doxazosin (16 mg, or the highest tolerated dose) for 4-weeks, followed by 4-week maintenance on placebo doxasozin. During this time subjects complete testing sessions (Self-administration, Cue session) assessing the abuse potential of intranasal oxycodone.
Anaphylactic reactions have occurred with injectables containing castor oil derivatives, including tacrolimus injection, in a small percentage of patients (0.6%). The exact cause of these reactions is not known. Tacrolimus injection should be reserved for patients who are unable to take tacrolimus orally. Monitor patients for anaphylaxis when using the intravenous route of administration [seeError! Hyperlink reference not valid.].
The efficacy and safety of Plerixafor Injection in conjunction with filgrastim in non-Hodgkin's lymphoma (NHL) Study AMD 3100-3101 (referred to as study 1) (NCT00103610) and multiple myeloma (MM) Study AMD 3100-3102 (referred to as study 2) (NCT00103662) were evaluated in two placebo-controlled studies (Studies 1 and 2). Patients were randomized to receive either Plerixafor Injection 0.24 mg/kg or placebo on each evening prior to apheresis. Patients received daily morning doses of filgrastim 10 mcg/kg for 4 days prior to the first dose of Plerixafor Injection or placebo and on each morning prior to apheresis. Two hundred and ninety-eight (298) NHL patients were included in the primary efficacy analyses for Study 1. The mean age was 55 years (range 29-75) and 58 years (range 22-75) in the Plerixafor Injection and placebo groups, respectively, and 93% of subjects were Caucasian. In study 2, 302 patients with MM were included in the primary efficacy analyses. The mean age (58 years) and age range (28-75) were similar in the Plerixafor Injection and placebo groups, and 81% of subjects were Caucasian. 

In Study 1, 59% of NHL patients who were mobilized with Plerixafor Injection and filgrastim collected ≥5 × 106 CD34+ cells/kg from the peripheral blood in four or fewer apheresis sessions, compared with 20% of patients who were mobilized with placebo and filgrastim (p <0.001). Other CD34+ cell mobilization outcomes showed similar findings (Table 5). 

The median number of days to reach ≥5 × 106 CD34+ cells/kg was 3 days for the Plerixafor Injection group and not evaluable for the placebo group. Table 6 presents the proportion of patients who achieved ≥5 × 106 CD34+ cells/kg by apheresis day. 

In Study 2, 72% of MM patients who were mobilized with Plerixafor Injection and filgrastim collected ≥6 × 106 CD34+ cells/kg from the peripheral blood in two or fewer apheresis sessions, compared with 34% of patients who were mobilized with placebo and filgrastim (p <0.001). Other CD34+ cell mobilization outcomes showed similar findings (Table 7). 

The median number of days to reach ≥6 × 106 CD34+ cells/kg was 1 day for the Plerixafor Injection group and 4 days for the placebo group. Table 8 presents the proportion of patients who achieved ≥6 × 106 CD34+ cells/kg by apheresis day. 

Multiple factors can influence time to engraftment and graft durability following stem cell transplantation. For transplanted patients in the Phase 3 studies, time to neutrophil and platelet engraftment and graft durability were similar across the treatment groups.
Investigators seek to study different strategies to identify women at highest risk for anal cancer. Primarily, investigators want to study a risk assessment called the Anal Cancer Risk Index; it gives women an overall number score based on risk factors that they may have for anal cancer, such as age, number of sexual partners, or smoking. The study team would like to determine whether women with higher Anal Cancer Risk Index scores are more likely to have abnormal results on anal pap smears, HPV tests, or anal biopsies. Next, the team will collect a swab of the cervix and swabs of the anus to study different laboratory tests that could identify women at highest risk of anal cancer: these tests include an anal pap smear and tests that detect HPV types most likely to cause cancer. Investigators would like to see which of these laboratory tests do the best job at predicting precancerous lesions in the anus. After collecting these swabs, women will have a procedure called high resolution anoscopy where investigators will look closely at the anus and biopsy any suspicious areas. Finally, the study team will look for HPV proteins and changes that HPV can make in cells to see if these tests predict anal lesions. The HPV protein is called E6 and E7 and the cell change test is called CADM1/MAL/miR-124-2. Investigators will measure E6/E7 and CADM1/MAL/miR-124-2 in cervical and anal samples to see if women positive for this marker are more likely to have abnormal results on anal pap smears or anal biopsies.
PURPOSE:To provide the titled antibody produced by the hybridoma formed by the fusion of the cell from the tumor line of mouse and the pancreatic cell of a mouse immunized with insulin. CONSTITUTION:The cell from the tumor line of mouse (e.g. P3-X63) is fused with the pancreatic cell of a mouse immunized with insulin, and the formed hybridoma is selected. The hybridoma is cloned twice or more to obtain a prefect monoclone. When the clone is established, the cell is cultured in vitro or in vivo to obtain a monoclonal anti-insulin antibody. The antibody has high specificity to insulin, and exhibits excellent effect when applied to the purification of insulin. High-purity insulin can be produced easily, in high yield, without necessitating a long and complicated process.
PROBLEM TO BE SOLVED: To obtain a propolis-containing food capable of improving the absorption efficiency of an active ingredient of a propolis extract in vivo and reducing a strong odor and mucosal irritation peculiar to the propolis extract and readily administrable without any water. SOLUTION: This propolis-containing food is obtained by making a propolis extract gel with a gelling base. A propolis extract prepared by extraction from the propolis by an alcohol extracting method is preferably used as the propolis extract. The content of the propolis extract is within the range of 2-25 wt.% in the propolis-containing food and the content of the gelling base is within the range of 0.01-10 wt.% in the propolis-containing food. A sulfated saccharide is preferably used as the gelling base in order to impart mucosal protecting actions to the propolis-containing food. Furthermore, a β-glucan is preferably used in order to impart immunopotentiating actions to the propolis-containing food.
Amoxapine is contraindicated in patients who have shown prior hypersensitivity to dibenzoxazepine compounds. It should not be given concomitantly with monoamine oxidase inhibitors. Hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressants and monoamine oxidase inhibitors simultaneously. When it is desired to replace a monoamine oxidase inhibitor with amoxapine, a minimum of 14 days should be allowed to elapse after the former is discontinued. Amoxapine should then be initiated cautiously with gradual increase in dosage until optimum response is achieved. The drug is not recommended for use during the acute recovery phase following myocardial infarction.
Retinal neovascularization (RNV) is a pathological process that primarily occurs in diabetic retinopathy, retinopathy of prematurity, and retinal vein occlusion. It is a common yet debilitating clinical condition that culminates in blindness. Urgent efforts are required to explore more efficient and less limiting therapeutic strategies. Key RNA-binding proteins (RBPs), crucial for post-transcriptional regulation of gene expression by binding to RNAs, are closely correlated with RNV development. RBP-RNA interactions are altered during RNV. Here, we briefly review the characteristics and functions of RBPs, and the mechanism of RNV. Then, we present insights into the role of the regulatory network of RBPs in RNV. HuR, eIF4E, LIN28B, SRSF1, METTL3, YTHDF1, Gal-1, HIWI1, and ZFR accelerate RNV progression, whereas YTHDF2 and hnRNPA2B1 hinder it. The mechanisms elucidated in this review provide a reference to guide the design of therapeutic strategies to reverse abnormal processes.